If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
CNTF-derived neurogenic peptide (DGGL core) with adamantane moiety
Research documentation
Ask sales for the P21 (P021) batch COA and the analytical evidence needed to qualify the material for your study. Confirm the available purity and identity records, lot continuity, handling information, and method requirements before ordering.
Overview
P21 (also written P021, or Peptide 6c in some reports) is a CNTF-derived neurotrophic mimetic: a capped hexapeptide, Ac-Asp-Gly-Gly-Leu-Ala-Gly-NH2 (Ac-DGGLAG-NH2), whose Asp-Gly-Gly-Leu (DGGL) N-terminal segment forms the active pharmacophore, fitted with an adamantane group that confers oral bioavailability and blood-brain-barrier passage. The compound originated with researchers at the New York State Institute for Basic Research, who set out to reproduce ciliary neurotrophic factor's neurogenic and BDNF-upregulating actions while avoiding CNTF's dose-limiting liabilities, and it appears in research on adult hippocampal neurogenesis, BDNF expression, and Alzheimer's and age-related cognitive-decline models. Lyochem supplies P21 as a lyophilized reference standard to a ≥99.0% HPLC purity specification. The adamantane group makes the molecule markedly more hydrophobic than the bare DGGLAG hexapeptide, so — as with other lipidated peptides — adequate resolution calls for adapted RP-HPLC conditions. Our batch COA reports peak-integration HPLC run under those conditions and ESI-MS confirming the adamantane-modified mass, with water content available on request; the 5 mg fill is matched to standard neuroscience aliquoting.
Applications & buyer fit
Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the published literature is intranasal — Semax, Selank, DSIP, Pinealon — because these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the CoA stage so the bioassay readout is not confounded by contamination unrelated to the test article.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Every lot has its own batch-specific CoA — HPLC purity and MS identity, plus any analytical scope agreed at quote stage — tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
Research peptide derivative; CAS is not consistently registered across suppliers. Sold for research use only.
Selected literature
Frequently asked questions
The N-terminal adamantane and the C-terminal amide make P21 substantially more hydrophobic than its bare peptide core, which shifts RP-HPLC behavior toward later elution and demands gradient conditions suited to a lipophilic analyte. Identity by ESI-MS should confirm a mass that includes the adamantane group and the amidated C-terminus, not just the DGGL-containing sequence, since the modification is part of the defining structure. Matching both the expected modified mass and the reference-standard retention confirms the analyst holds the intact delivery construct rather than an unconjugated or partially deprotected peptide.
P21 is presented as the Ac-DGGLAG-NH2 hexapeptide bearing the adamantane group, not simply its active DGGL core. The N-terminal acetyl and C-terminal amide each alter the intact mass and, together with the adamantane, contribute the aminopeptidase resistance the molecule depends on. Verifying identity therefore means confirming a mass consistent with all three modifications on the full hexapeptide and an RP-HPLC profile matching the qualified reference, so that any assay of CNTF-mimetic neurogenic activity uses the fully modified construct rather than a truncated or under-capped variant with different stability.
Related peptides